Rep. Norm Thurston — Voting Record

Utah House District 62 · complete roll-call record from le.utah.gov
← All votes

Bill

Kratom Adjustments
Number
S.B. 45 (2026GS)
Sponsor
Sen. McKell, Michael K.
Final action
Governor Signed 3/26/2026
Outcome
Became law — signed by Gov. Spencer J. Cox

Summary

This bill amends provisions related to kratom.

What it does

  • This bill:
  • defines terms;
  • requires a kratom processor and kratom retailer to register with the Department of Agriculture and Food;
  • only allows a retail tobacco specialty business to sell kratom;
  • bans the sale of certain kratom products;
  • amends provisions related to penalties and fees;
  • amends the age for who can purchase a kratom product;
  • schedules 7-hydroxymitragynine, including synthetics, if the 7-hydroxymitragynine concentration exceeds a certain percentage as a schedule I controlled substance; and
  • schedules Mitragynine pseudoindoxyl, including synthetics; and
  • includes a coordination clause with H.B. 387, Kratom Modifications, directing the Legislature to not enroll H.B. 387.

Every vote on this bill

2026-01-26Senate Comm - Favorable Recommendation
Senate Business and Labor Committee
7-1-0not eligible / no record
2026-02-24House Comm - Substitute Recommendation
House Business, Labor, and Commerce Committee
12-0-4YEA
2026-02-24House Comm - Favorable Recommendation
House Business, Labor, and Commerce Committee
13-0-3YEA
2026-03-04House/ substituted
House 3rd Reading Calendar for Senate bills
0-0-75not eligible / no record
2026-03-04House/ circled
House 3rd Reading Calendar for Senate bills
0-0-75not eligible / no record
2026-03-04House/ uncircled
House 3rd Reading Calendar for Senate bills
0-0-75not eligible / no record
2026-03-04House/ floor amendment failed
House 3rd Reading Calendar for Senate bills
0-0-75not eligible / no record
2026-03-04House/ substitute adoption failed
House 3rd Reading Calendar for Senate bills
0-0-75not eligible / no record
2026-03-04House/ passed 3rd reading
Senate Secretary
63-10-2YEA
2026-03-04Senate/ concurs with House amendment
House Speaker
26-0-3not eligible / no record
2026-02-06Senate/ substitute adoption failed
Senate 2nd Reading Calendar
0-0-29not eligible / no record
2026-02-06Senate/ passed 2nd reading
Senate 3rd Reading Calendar
24-4-1not eligible / no record
2026-02-09Senate/ circled
Senate 3rd Reading Calendar
0-0-29not eligible / no record
2026-02-18Senate/ uncircled
Senate 3rd Reading Calendar
0-0-29not eligible / no record
2026-02-18Senate/ substituted
Senate 3rd Reading Calendar
0-0-29not eligible / no record
2026-02-18Senate/ passed 3rd reading
Clerk of the House
29-0-0not eligible / no record

Bill text

enrolled version · official source
30
4-45-101
4-45-102
4-45-103
4-45-104
4-45-105
4-45-108
58-37-3.4
58-37-4
0
Kratom Adjustments
2026 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Michael K. McKell
House Sponsor: Katy Hall
Cosponsor:
Jennifer Dailey-Provost
Brady Brammer
LONG TITLE
General Description:
This bill amends provisions related to kratom.
Highlighted Provisions:
This bill:
defines terms;
requires a kratom processor and kratom retailer to register with the Department of 
Agriculture and Food;
only allows a retail tobacco specialty business to sell kratom;
bans the sale of certain kratom products;
amends provisions related to penalties and fees;
amends the age for who can purchase a kratom product;
schedules 7-hydroxymitragynine, including synthetics, if the 7-hydroxymitragynine 
concentration exceeds a certain percentage as a schedule I controlled substance; and
schedules Mitragynine pseudoindoxyl, including synthetics.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
4-45-102
, as enacted by Laws of Utah 2019, Chapter 329
4-45-103
, as enacted by Laws of Utah 2019, Chapter 329
4-45-104
, as enacted by Laws of Utah 2019, Chapter 329
4-45-105
, as enacted by Laws of Utah 2019, Chapter 329
4-45-108
, as enacted by Laws of Utah 2019, Chapter 329
58-37-4
, as last amended by Laws of Utah 2025, Chapter 216
ENACTS:
58-37-3.4
, Utah Code Annotated 1953
REPEALS:
4-45-101
, as enacted by Laws of Utah 2019, Chapter 329
Be it enacted by the Legislature of the state of Utah:
Section 1. Section 
4-45-102
 is amended to read:
45. Kratom Regulation Act
4-45-102
. Definitions.
As used in this chapter:
(1)
"Commissioner" means the commissioner of the department.
(2)
"Department" means the Department of Agriculture and Food created in Section 
4-2-102
.
(3)
"Food" means:
(a)
an article used for food or drink for human or animal consumption or the 
components of the article;
(b)
chewing gum or chewing gum components; or
(c)
a food supplement for special dietary use that is necessitated because of a physical, 
physiological, pathological, or other condition.
(1)
"Kratom extract" means a preparation containing any part of the Mitragyna speciosa 
plant in a concentrated form.
(4)
(2)
"Kratom processor" means a person who
:
(a)
sells, prepares, or maintains 
 prepares, processes, manufactures, or distributes 
a 
kratom product
; or
.
(b)
advertises, represents, or holds oneself out as selling, preparing, or maintaining a 
kratom product.
(5)
(3)
"Kratom product" 
mean food
means a product
 containing any part of a leaf of the 
plant Mitragyna speciosa.
(4)
"Kratom retailer" means a person who sells a kratom product for retail sale in the state.
(5)
"Pure leaf kratom" means a kratom product that:
(a)
is identifiable as plant matter or is identifiable plant matter contained in an 
encapsulating agent described in Subsection 
(5)(b)
;
(b)
is not mixed or packed with a nonkratom substance unless the nonkratom substance 
is an inert encapsulating agent that:
(i)
is composed of food-grade or pharmaceutical-grade materials with no 
pharmacological activity;
(ii)
contains no psychoactive substances, stimulants, or adulterants; and
(iii)
serves solely to contain or deliver the plant matter;
(c)
does not contain any kratom extract; and
(d)
does not contain 7-hydroxymitragynine at a level greater than 0.4% of the total 
kratom alkaloid composition of the product.
(6)
"Total kratom alkaloid composition" means the total amount of all alkaloids derived 
from the Mitragyna speciosa plant.
Section 2. Section 
4-45-103
 is amended to read:
4-45-103
. Factual basis for claim as kratom product required -- Administrative 
penalty -- Request for hearing.
(1)
A kratom processor shall disclose on the product label of each kratom product that the 
kratom processor prepares, distributes, sells, or offers for sale the factual basis upon 
which the kratom processor represents the 
food
product
 as a kratom product.
(2)
For a violation of Subsection 
(1)
, a kratom processor is subject to an administrative fine 
of:
up to $5,000.
(a)
up to $500 for the first offense; and
(b)
up to $1,000 for a second or subsequent offense.
(3)
Upon the request of a kratom processor fined under this section, the commissioner shall 
conduct a hearing in accordance with 
Title 63G, Chapter 4, Administrative Procedures 
Act
.
Section 3. Section 
4-45-104
 is amended to read:
4-45-104
. Kratom processor and kratom retailer requirements -- Criminal 
penalty.
(1)
A kratom processor
 or kratom retailer
 may not prepare,
 possess,
 distribute, sell, or offer 
for sale a kratom product
 that
:
(a)
that is mixed or packed with a nonkratom substance that affects the quality or 
strength of the kratom product to such a degree as to render the kratom product 
injurious to a consumer;
is not pure leaf kratom; and
(b)
that contains a poisonous or otherwise deleterious nonkratom ingredient, including a 
controlled substance as defined in Section 
58-37-2
;
(c)
containing a level of 7-hydroxymitragynine in the alkaloid fraction that is greater 
than 2% of the alkaloid composition of the kratom product;
(d)
containing a synthetic alkaloid, including synthetic mitragynine, synthetic 
7-hydroxymitragynine, or any other synthetically derived compound of the kratom 
plant; or
(e)
(b)
that 
does not include a product label on the kratom product packaging that 
states the amount of mitragynine and 7-hydroxymitragynine contained in the 
packaged kratom product.
(2)
A kratom processor
 or kratom retailer
 who violates Subsection 
(1)
 is guilty of
:
(a)
 a class 
C
B
 misdemeanor for 
each violation.
the first violation;
(b)
a class A misdemeanor for a second violation; and
(c)
a third degree felony for any subsequent violation.
(3)
A kratom processor does not violate Subsection 
(1)
 if the kratom processor shows by a 
preponderance of the evidence that the kratom processor relied in good faith upon the 
representation of a manufacturer, processor, packer, or distributor of food represented to 
be a kratom product.
(4)
(3)
A kratom processor
 or kratom retailer
 may not prepare, distribute, sell, or offer for 
sale a kratom product that is not registered with the department in accordance with this 
chapter.
(5)
(4)
(a)
A kratom processor shall register as a food establishment in accordance with 
Section 
4-5-301
 and with the department as a kratom processor
.
(b)
A kratom retailer shall register with the department as a kratom retailer.
(c)
The department may not register a person as a kratom retailer unless the kratom 
retailer is licensed as a retail tobacco specialty business under Sections 
10-8-41.6
 and 
17-78-1004
.
(d)
The department shall set a fee to register the following:
(i)
a kratom processor; and
(ii)
a kratom retailer.
(e)
The department shall:
(i)
set an administrative fine not to exceed $5,000 for a person who sells a kratom 
product if the person is not registered as a kratom processor or kratom retailer 
with the department; and
(ii)
assess the fine described in Subsection 
(4)(e)(i)
 against any person who offers a 
kratom product for sale in this state if the person is not registered as a kratom 
processor or kratom retailer.
(5)
Notwithstanding Subsection 
(1)(a)
, until March 6, 2027, a kratom processor may 
prepare, possess, distribute, sell, or offer for sale a kratom product that is not a pure leaf 
kratom product if the kratom product:
(a)
is not offered for retail sale or distribution in this sta
te;
(b)
is manufactured and distributed for lawful sale in another state; and
(c)
does not contain 7-hydroxymitragynine at a level greater than 0.4% of the total 
kratom alkaloid composition of the product.
Section 4. Section 
4-45-105
 is amended to read:
4-45-105
. Prohibition on sale to minors -- Criminal penalty.
(1)
A kratom processor
 or kratom retailer
 may not distribute, sell, or offer for sale a kratom 
product to an individual under 
18
21
 years
 of age
 old
.
(2)
A kratom processor
 or kratom retailer
 who violates this section is guilty of a class 
C
A
misdemeanor for each violation.
Section 5. Section 
4-45-108
 is amended to read:
4-45-108
. Registration of kratom products -- Department duties.
(1)
The department shall set a fee to register a kratom product, in accordance with Section 
4-2-103
.
(2)
The fee described in Subsection 
(1)
 may be paid by 
a producer, manufacturer, or 
distributor of a kratom product
any person
, but a kratom product may not be registered 
with the department until the fee is paid.
(3)
The department shall:
(a)
set an administrative fine
, larger than the fee described in Subsection 
(1)
, 
 not to 
exceed $5,000 
for a person who sells a kratom product that is not registered with the 
department; and
(b)
assess the fine described in Subsection 
(3)(a)
 against any person who offers an 
unregistered kratom product for sale in this state.
(4)
The department may seize and destroy any unregistered kratom product offered for sale 
in this state.
Section 6. Section 
58-37-3.4
 is enacted to read:
58-37-3.4
. Exemption for 7-hydroxymitragyine in kratom products.
(1)
As used in this section, "pure leaf kratom" means the same as that term is defined in 
Section 
4-45-102
.
(2)
Notwithstanding any other provision of this chapter a person who possesses, 
manufacturers, or distributes pure leaf kratom is not subject to the penalties described in 
this title for the possession, manufacture, or distribution of 7-hydroxymitragynine to the 
extent that the person's possession, manufacture, or distribution of the pure leaf kratom 
complies with Title 4, Chapter 45, Kratom Regulation Act.
(3)
Notwithstanding any other provision of this chapter and until March 6, 2027, a person 
who possesses, manufacturers, or distributes a kratom product in accordance with 
Subsection 
4-45-104(5)
 is not subject to the penalties described in this title for the 
possession, manufacture, or distribution of 7-hydroxymitragine.
Section 7. Section 
58-37-4
 is amended to read:
58-37-4
. Schedules of controlled substances -- Schedules I through V -- Findings 
required -- Specific substances included in schedules.
(1)
There are established five schedules of controlled substances known as Schedules I, II, 
III, IV, and V which consist of substances listed in this section.
(2)
Schedules I, II, III, IV, and V consist of the following drugs or other substances by the 
official name, common or usual name, chemical name, or brand name designated:
(a)
Schedule I:
(i)
Unless specifically excepted or unless listed in another schedule, any of the 
following opiates, including their isomers, esters, ethers, salts, and salts of 
isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and 
salts is possible within the specific chemical designation:
(A)
Acetyl-alpha-methylfentanyl 
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(B)
Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(C)
Acetylmethadol;
(D)
Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);
(E)
Allylprodine;
(F)
Alphacetylmethadol, except levo-alphacetylmethadol also known as 
levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
(G)
Alphameprodine;
(H)
Alphamethadol;
(I)
Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] 
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
(J)
Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4- 
piperidinyl]-N-phenylpropanamide);
(K)
Benzylpiperazine;
(L)
Benzethidine;
(M)
Betacetylmethadol;
(N)
Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- 
piperidinyl]-N-phenylpropanamide);
(O)
Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2- 
phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
(P)
Betameprodine;
(Q)
Betamethadol;
(R)
Betaprodine;
(S)
Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
(T)
Clonitazene;
(U)
Cyclopropyl fentanyl 
(N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
(V)
Dextromoramide;
(W)
Diampromide;
(X)
Diethylthiambutene;
(Y)
Difenoxin;
(Z)
Dimenoxadol;
(AA)
Dimepheptanol;
(BB)
Dimethylthiambutene;
(CC)
Dioxaphetyl butyrate;
(DD)
Dipipanone;
(EE)
Ethylmethylthiambutene;
(FF)
Etizolam 
(1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
(GG)
Etonitazene;
(HH)
Etoxeridine;
(II)
Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] 
furan-2-carboxamide);
(JJ)
Furethidine;
(KK)
Hydroxypethidine;
(LL)
Ketobemidone;
(MM)
Levomoramide;
(NN)
Levophenacylmorphan;
(OO)
Methoxyacetyl fentanyl 
(2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);
(PP)
Morpheridine;
(QQ)
MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(RR)
Noracymethadol;
(SS)
Norlevorphanol;
(TT)
Normethadone;
(UU)
Norpipanone;
(VV)
Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl] 
propanamide);
(WW)
Para-fluoroisobutyryl fentanyl 
(N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
(XX)
PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(YY)
Phenadoxone;
(ZZ)
Phenampromide;
(AAA)
Phenibut;
(BBB)
Phenomorphan;
(CCC)
Phenoperidine;
(DDD)
Piritramide;
(EEE)
Proheptazine;
(FFF)
Properidine;
(GGG)
Propiram;
(HHH)
Racemoramide;
(III)
Tetrahydrofuran fentanyl 
(N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
(JJJ)
Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
(KKK)
Tianeptine;
(LLL)
Tilidine;
(MMM)
Trimeperidine;
(NNN)
3-methylfentanyl, including the optical and geometric isomers 
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);
(OOO)
3-methylthiofentanyl 
(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(PPP)
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also 
known as U-47700; and
(QQQ)
4-cyano CUMYL-BUTINACA.
(ii)
Unless specifically excepted or unless listed in another schedule, any of the 
following opium derivatives, their salts, isomers, and salts of isomers when the 
existence of the salts, isomers, and salts of isomers is possible within the specific 
chemical designation:
(A)
Acetorphine;
(B)
Acetyldihydrocodeine;
(C)
Benzylmorphine;
(D)
Codeine methylbromide;
(E)
Codeine-N-Oxide;
(F)
Cyprenorphine;
(G)
Desomorphine;
(H)
Dihydromorphine;
(I)
Drotebanol;
(J)
Etorphine (except hydrochloride salt);
(K)
Heroin;
(L)
Hydromorphinol;
(M)
Methyldesorphine;
(N)
Methylhydromorphine;
(O)
Morphine methylbromide;
(P)
Morphine methylsulfonate;
(Q)
Morphine-N-Oxide;
(R)
Myrophine;
(S)
Nicocodeine;
(T)
Nicomorphine;
(U)
Normorphine;
(V)
Pholcodine; and
(W)
Thebacon.
(iii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
hallucinogenic substances, or which contains any of their salts, isomers, and salts 
of isomers when the existence of the salts, isomers, and salts of isomers is possible 
within the specific chemical designation; as used in this Subsection 
(2)(a)(iii)
only, "isomer" includes the optical, position, and geometric isomers:
(A)
Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; 
-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; 
-ET; and AET;
(B)
4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 
4-bromo-2,5-dimethoxy-
-methylphenethylamine; 4-bromo-2,5-DMA;
(C)
4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: 
2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 
2C-B, Nexus;
(D)
2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy-
-methylphenethylamine; 2,5-DMA;
(E)
2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
(F)
4-methoxyamphetamine, some trade or other names: 4-methoxy-
-methylphenethylamine; paramethoxyamphetamine, PMA;
(G)
5-methoxy-3,4-methylenedioxyamphetamine;
(H)
4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 
4-methyl-2,5-dimethoxy-
-methylphenethylamine; "DOM"; and "STP";
(I)
3,4-methylenedioxy amphetamine;
(J)
3,4-methylenedioxymethamphetamine (MDMA);
(K)
3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl- 
alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, 
MDEA;
(L)
N-hydroxy-3,4-methylenedioxyamphetamine, also known as 
N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy 
MDA;
(M)
3,4,5-trimethoxy amphetamine;
(N)
Bufotenine, some trade and other names: 3-(
-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; 
N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
(O)
Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
(P)
Dimethyltryptamine, some trade or other names: DMT;
(Q)
Ibogaine, some trade and other names: 7-Ethyl-6,6
,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] 
azepino [5,4-b] indole; Tabernanthe iboga;
(R)
Lysergic acid diethylamide;
(S)
Marijuana;
(T)
Mescaline;
(U)
Parahexyl, some trade or other names: 
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; 
Synhexyl;
(V)
Peyote, meaning all parts of the plant presently classified botanically as 
Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any 
extract from any part of such plant, and every compound, manufacture, salts, 
derivative, mixture, or preparation of such plant, its seeds or extracts 
(Interprets 21 USC 812(c), Schedule I(c) (12));
(W)
N-ethyl-3-piperidyl benzilate;
(X)
N-methyl-3-piperidyl benzilate;
(Y)
Psilocybin;
(Z)
Psilocyn;
(AA)
Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis 
(cannabis plant), except for marijuana as defined in Subsection 
58-37-2(1)(aa)(i)(E)
, as well as synthetic equivalents of the substances 
contained in the cannabis plant, or in the resinous extractives of Cannabis, sp. 
and/or synthetic substances, derivatives, and their isomers with similar 
chemical structure and pharmacological activity to those substances contained 
in the plant, such as the following: 
1 cis or trans tetrahydrocannabinol, and 
their optical isomers 
6 cis or trans tetrahydrocannabinol, and their optical 
isomers 
3,4 cis or trans tetrahydrocannabinol, and its optical isomers, and since 
nomenclature of these substances is not internationally standardized, 
compounds of these structures, regardless of numerical designation of atomic 
positions covered;
(BB)
Ethylamine analog of phencyclidine, some trade or other names: 
N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, 
N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
(CC)
Pyrrolidine analog of phencyclidine, some trade or other names: 
1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
(DD)
Thiophene analog of phencyclidine, some trade or other names: 
1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, 
TPCP, TCP; and
(EE)
1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
(iv)
Unless specifically excepted or unless listed in another schedule, any material 
compound, mixture, or preparation which contains any quantity of the following 
substances having a depressant effect on the central nervous system, including its 
salts, isomers, and salts of isomers when the existence of the salts, isomers, and 
salts of isomers is possible within the specific chemical designation:
(A)
Mecloqualone; and
(B)
Methaqualone.
(v)
Any material, compound, mixture, or preparation containing any quantity of the 
following substances having a stimulant effect on the central nervous system, 
including their salts, isomers, and salts of isomers:
(A)
Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 
or 4,5-dihydro-5-phenyl-2-oxazolamine;
(B)
Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, 
alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
(C)
Fenethylline;
(D)
Methcathinone, some other names: 2-(methylamino)-propiophenone; 
alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; 
alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; 
N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432, 
its salts, optical isomers, and salts of optical isomers;
(E)
(
)cis-4-methylaminorex ((
)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
(F)
N-ethylamphetamine; and
(G)
N,N-dimethylamphetamine, also known as 
N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
(vi)
Any material, compound, mixture, or preparation which contains any quantity of 
the following substances, including their optical isomers, salts, and salts of 
isomers, subject to temporary emergency scheduling:
(A)
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
(B)
N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
(vii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of gamma 
hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and 
salts of isomers.
(viii)
Unless specifically excepted or unless listed in another schedule, the following 
substances commonly found in Mitragyna speciosa, including synthetic versions, 
isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the 
existence of the isomers, esters, ethers, and salts is possible within the specific 
chemical designation:
(A)
7-hydroxymitragynine (methyl 
(E)-2[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate); 
and
(B)
Mitragynine pseudoindoxyl (methyl 
(E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3-oxospiro[1H-indole-2,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate).
(b)
Schedule II:
(i)
Unless specifically excepted or unless listed in another schedule, any of the 
following substances whether produced directly or indirectly by extraction from 
substances of vegetable origin, or independently by means of chemical synthesis, 
or by a combination of extraction and chemical synthesis:
(A)
Opium and opiate, and any salt, compound, derivative, or preparation of 
opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, 
naloxone, and naltrexone, and their respective salts, but including:
(I)
Raw opium;
(II)
Opium extracts;
(III)
Opium fluid;
(IV)
Powdered opium;
(V)
Granulated opium;
(VI)
Tincture of opium;
(VII)
Codeine;
(VIII)
Ethylmorphine;
(IX)
Etorphine hydrochloride;
(X)
Hydrocodone;
(XI)
Hydromorphone;
(XII)
Metopon;
(XIII)
Morphine;
(XIV)
Oxycodone;
(XV)
Oxymorphone; and
(XVI)
Thebaine;
(B)
Any salt, compound, derivative, or preparation which is chemically equivalent 
or identical with any of the substances referred to in Subsection 
(2)(b)(i)(A)
, 
except that these substances may not include the isoquinoline alkaloids of 
opium;
(C)
Opium poppy and poppy straw;
(D)
Coca leaves and any salt, compound, derivative, or preparation of coca leaves, 
and any salt, compound, derivative, or preparation which is chemically 
equivalent or identical with any of these substances, and includes cocaine and 
ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives, 
whether derived from the coca plant or synthetically produced, except the 
substances may not include decocainized coca leaves or extraction of coca 
leaves, which extractions do not contain cocaine or ecgonine; and
(E)
Concentrate of poppy straw, which means the crude extract of poppy straw in 
either liquid, solid, or powder form which contains the phenanthrene alkaloids 
of the opium poppy.
(ii)
Unless specifically excepted or unless listed in another schedule, any of the 
following opiates, including their isomers, esters, ethers, salts, and salts of 
isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and 
salts is possible within the specific chemical designation, except dextrorphan and 
levopropoxyphene:
(A)
Alfentanil;
(B)
Alphaprodine;
(C)
Anileridine;
(D)
Bezitramide;
(E)
Bulk dextropropoxyphene (nondosage forms);
(F)
Carfentanil;
(G)
Dihydrocodeine;
(H)
Diphenoxylate;
(I)
Fentanyl;
(J)
Isomethadone;
(K)
Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol, 
levomethadyl acetate, or LAAM;
(L)
Levomethorphan;
(M)
Levorphanol;
(N)
Metazocine;
(O)
Methadone;
(P)
Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
(Q)
Moramide-Intermediate, 2-methyl-3-morpholino-1, 
1-diphenylpropane-carboxylic acid;
(R)
Pethidine (meperidine);
(S)
Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
(T)
Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
(U)
Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
(V)
Phenazocine;
(W)
Piminodine;
(X)
Racemethorphan;
(Y)
Racemorphan;
(Z)
Remifentanil; and
(AA)
Sufentanil.
(iii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a stimulant effect on the central nervous system:
(A)
Amphetamine, its salts, optical isomers, and salts of its optical isomers;
(B)
Methamphetamine, its salts, isomers, and salts of its isomers;
(C)
Phenmetrazine and its salts; and
(D)
Methylphenidate.
(iv)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a depressant effect on the central nervous system, including its 
salts, isomers, and salts of isomers when the existence of the salts, isomers, and 
salts of isomers is possible within the specific chemical designation:
(A)
Amobarbital;
(B)
Glutethimide;
(C)
Pentobarbital;
(D)
Phencyclidine;
(E)
Phencyclidine immediate precursors: 1-phenylcyclohexylamine and 
1-piperidinocyclohexanecarbonitrile (PCC); and
(F)
Secobarbital.
(v)
(A)
Unless specifically excepted or unless listed in another schedule, any 
material, compound, mixture, or preparation which contains any quantity of 
Phenylacetone.
(B)
Some of these substances may be known by trade or other names: 
phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
(vi)
Nabilone, another name for nabilone: (
)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6, 
6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
(vii)
A drug product or preparation that contains any component of marijuana, 
including tetrahydrocannabinol, and is approved by the United States Food and 
Drug Administration and scheduled by the Drug Enforcement Administration in 
Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.
(c)
Schedule III:
(i)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a stimulant effect on the central nervous system, including its 
salts, isomers whether optical, position, or geometric, and salts of the isomers 
when the existence of the salts, isomers, and salts of isomers is possible within the 
specific chemical designation:
(A)
Those compounds, mixtures, or preparations in dosage unit form containing 
any stimulant substances listed in Schedule II, which compounds, mixtures, or 
preparations were listed on August 25, 1971, as excepted compounds under 
Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other 
drug of the quantitive composition shown in that list for those drugs or which 
is the same except that it contains a lesser quantity of controlled substances;
(B)
Benzphetamine;
(C)
Chlorphentermine;
(D)
Clortermine; and
(E)
Phendimetrazine.
(ii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a depressant effect on the central nervous system:
(A)
Any compound, mixture, or preparation containing amobarbital, secobarbital, 
pentobarbital, or any salt of any of them, and one or more other active 
medicinal ingredients which are not listed in any schedule;
(B)
Any suppository dosage form containing amobarbital, secobarbital, or 
pentobarbital, or any salt of any of these drugs which is approved by the 
United 
States 
Food and Drug Administration for marketing only as a suppository;
(C)
Any substance which contains any quantity of a derivative of barbituric acid 
or any salt of any of them;
(D)
Chlorhexadol;
(E)
Buprenorphine;
(F)
Any drug product containing gamma hydroxybutyric acid, including its salts, 
isomers, and salts of isomers, for which an application is approved under the 
federal Food, Drug, and Cosmetic Act, Section 505;
(G)
Ketamine, its salts, isomers, and salts of isomers, some other names for 
ketamine: 
 -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
(H)
Lysergic acid;
(I)
Lysergic acid amide;
(J)
Methyprylon;
(K)
Sulfondiethylmethane;
(L)
Sulfonethylmethane;
(M)
Sulfonmethane; and
(N)
Tiletamine and zolazepam or any of their salts, some trade or other names for 
a tiletamine-zolazepam combination product: Telazol, some trade or other 
names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade 
or other names for zolazepam: 
4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] 
[1,4]-diazepin-7(1H)-one, flupyrazapon.
(iii)
Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in 
a U.S. Food and Drug Administration approved drug product, some other names 
for dronabinol: 
(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, 
or (-)-delta-9-(trans)-tetrahydrocannabinol.
(iv)
Nalorphine.
(v)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation containing limited quantities of any of the 
following narcotic drugs, or their salts calculated as the free anhydrous base or 
alkaloid:
(A)
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 
milligrams per dosage unit, with an equal or greater quantity of an isoquinoline 
alkaloid of opium;
(B)
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 
milligrams per dosage unit, with one or more active non-narcotic ingredients in 
recognized therapeutic amounts;
(C)
Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not 
more than 15 milligrams per dosage unit, with a fourfold or greater quantity of 
an isoquinoline alkaloid of opium;
(D)
Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not 
more than 15 milligrams per dosage unit, with one or more active, non-narcotic 
ingredients in recognized therapeutic amounts;
(E)
Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more 
than 90 milligrams per dosage unit, with one or more active non-narcotic 
ingredients in recognized therapeutic amounts;
(F)
Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more 
than 15 milligrams per dosage unit, with one or more active, non-narcotic 
ingredients in recognized therapeutic amounts;
(G)
Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, 
or not more than 25 milligrams per dosage unit, with one or more active, 
non-narcotic ingredients in recognized therapeutic amounts; and
(H)
Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams 
with one or more active, non-narcotic ingredients in recognized therapeutic 
amounts.
(vi)
Unless specifically excepted or unless listed in another schedule, anabolic 
steroids including any of the following or any isomer, ester, salt, or derivative of 
the following that promotes muscle growth:
(A)
Boldenone;
(B)
Chlorotestosterone (4-chlortestosterone);
(C)
Clostebol;
(D)
Dehydrochlormethyltestosterone;
(E)
Dihydrotestosterone (4-dihydrotestosterone);
(F)
Drostanolone;
(G)
Ethylestrenol;
(H)
Fluoxymesterone;
(I)
Formebulone (formebolone);
(J)
Mesterolone;
(K)
Methandienone;
(L)
Methandranone;
(M)
Methandriol;
(N)
Methandrostenolone;
(O)
Methenolone;
(P)
Methyltestosterone;
(Q)
Mibolerone;
(R)
Nandrolone;
(S)
Norethandrolone;
(T)
Oxandrolone;
(U)
Oxymesterone;
(V)
Oxymetholone;
(W)
Stanolone;
(X)
Stanozolol;
(Y)
Testolactone;
(Z)
Testosterone; and
(AA)
Trenbolone.
(vii)
Anabolic steroids expressly intended for administration through implants to 
cattle or other nonhuman species, and approved by the Secretary of Health and 
Human Services for use, may not be classified as a controlled substance.
(viii)
A drug product or preparation that contains any component of marijuana, 
including tetrahydrocannabinol, and is approved by the United States Food and 
Drug Administration and scheduled by the Drug Enforcement Administration in 
Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.
(ix)
Nabiximols.
(d)
Schedule IV:
(i)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation containing not more than 1 milligram of 
difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or 
any salts of any of them.
(ii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances, including its salts, isomers, and salts of isomers when the existence of 
the salts, isomers, and salts of isomers is possible within the specific chemical 
designation:
(A)
Alprazolam;
(B)
Barbital;
(C)
Bromazepam;
(D)
Butorphanol;
(E)
Camazepam;
(F)
Carisoprodol;
(G)
Chloral betaine;
(H)
Chloral hydrate;
(I)
Chlordiazepoxide;
(J)
Clobazam;
(K)
Clonazepam;
(L)
Clorazepate;
(M)
Clotiazepam;
(N)
Cloxazolam;
(O)
Delorazepam;
(P)
Diazepam;
(Q)
Dichloralphenazone;
(R)
Estazolam;
(S)
Ethchlorvynol;
(T)
Ethinamate;
(U)
Ethyl loflazepate;
(V)
Fludiazepam;
(W)
Flunitrazepam;
(X)
Flurazepam;
(Y)
Halazepam;
(Z)
Haloxazolam;
(AA)
Ketazolam;
(BB)
Loprazolam;
(CC)
Lorazepam;
(DD)
Lormetazepam;
(EE)
Mebutamate;
(FF)
Medazepam;
(GG)
Meprobamate;
(HH)
Methohexital;
(II)
Methylphenobarbital (mephobarbital);
(JJ)
Midazolam;
(KK)
Nimetazepam;
(LL)
Nitrazepam;
(MM)
Nordiazepam;
(NN)
Oxazepam;
(OO)
Oxazolam;
(PP)
Paraldehyde;
(QQ)
Pentazocine;
(RR)
Petrichloral;
(SS)
Phenobarbital;
(TT)
Pinazepam;
(UU)
Prazepam;
(VV)
Quazepam;
(WW)
Temazepam;
(XX)
Tetrazepam;
(YY)
Tramadol;
(ZZ)
Triazolam;
(AAA)
Zaleplon; and
(BBB)
Zolpidem.
(iii)
Any material, compound, mixture, or preparation of fenfluramine which contains 
any quantity of the following substances, including its salts, isomers whether 
optical, position, or geometric, and salts of the isomers when the existence of the 
salts, isomers, and salts of isomers is possible.
(iv)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a stimulant effect on the central nervous system, including its 
salts, isomers whether optical, position, or geometric isomers, and salts of the 
isomers when the existence of the salts, isomers, and salts of isomers is possible 
within the specific chemical designation:
(A)
Cathine ((+)-norpseudoephedrine);
(B)
Diethylpropion;
(C)
Fencamfamine;
(D)
Fenproprex;
(E)
Mazindol;
(F)
Mefenorex;
(G)
Modafinil;
(H)
Pemoline, including organometallic complexes and chelates thereof;
(I)
Phentermine;
(J)
Pipradrol;
(K)
Sibutramine; and
(L)
SPA ((-)-1-dimethylamino-1,2-diphenylethane).
(v)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of 
dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 
2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
(vi)
A drug product or preparation that contains any component of marijuana and is 
approved by the United States Food and Drug Administration and scheduled by 
the Drug Enforcement Administration in Schedule IV of the federal Controlled 
Substances Act, Title II, P.L. 91-513.
(e)
Schedule V:
(i)
Any compound, mixture, or preparation containing any of the following limited 
quantities of narcotic drugs, or their salts calculated as the free anhydrous base or 
alkaloid, which includes one or more non-narcotic active medicinal ingredients in 
sufficient proportion to confer upon the compound, mixture, or preparation 
valuable medicinal qualities other than those possessed by the narcotic drug alone:
(A)
not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
(B)
not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 
grams;
(C)
not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 
grams;
(D)
not more than 2.5 milligrams of diphenoxylate and not less than 25 
micrograms of atropine sulfate per dosage unit;
(E)
not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
(F)
not more than 0.5 milligram of difenoxin and not less than 25 micrograms of 
atropine sulfate per dosage unit; and
(G)
unless specifically exempted or excluded or unless listed in another schedule, 
any material, compound, mixture, or preparation which contains Pyrovalerone 
having a stimulant effect on the central nervous system, including its salts, 
isomers, and salts of isomers.
(ii)
A drug product or preparation that contains any component of marijuana, 
including cannabidiol, and is approved by the United States Food and Drug 
Administration and scheduled by the Drug Enforcement Administration in 
Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513. 
(iii)
Gabapentin.
Section 8. 
Repealer.
Title.
Section 9. 
Effective Date.
This bill takes effect on 
May 6, 2026
.
3-11-26 4:03 PM